Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06715579Recruiting

Cardiac Angiosarcoma International Registry

Role: lead

NCT05430971Recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Role: lead

NCT06322108Phase 2Recruiting

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

Role: lead

NCT05891821Phase 2Recruiting

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Role: lead

NCT05711992Recruiting

Rare Embryonal Tumors of the Central Nervous System: International Registry

Role: lead

NCT05872893Phase 3Unknown

Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone

Role: lead

All 6 trials loaded